Search Results - "Velleca, A."

The New UNOS Heart Allocation Changes Significantly Changed the Landscape of Heart Transplantation by Ramzy, D., Esmailian, F., Emerson, D., Megna, D., Levine, R., Cole, R., Passano, E., Runyan, C., Velleca, A., Kobashigawa, J., Moriguchi, J.

“…October 2018 saw a change in the UNOS heart allocation which prioritized the sickest patients especially those of temporary devices. The main driver of the…”
Get full text

Desensitization Therapy for Mechanical Circulatory Support Patients with Existing Driveline Infection: Is It Safe with Current Desensitization Therapies? by Kittleson, M., Patel, J., Kransdorf, E., Shen, A., Nishihara, K., Rajkumar, S., Velleca, A., Geft, D., Czer, L., Moriguchi, J., Kobashigawa, J.

“…Patients with end-stage heart failure may undergo mechanical circulatory support (MCS) as a bridge to transplant. This strategy may be complicated by…”
Get full text

Does the Dose of Mycophenolate Mofetil Impact Outcome after Heart Transplantation? by Patel, J., Kittleson, M., Chang, D.H., Nishihara, K., Shen, A., Mersola, S., Velleca, A., Hage, A., Czer, L., Emerson, D., Kobashigawa, J.A.

“…Mycophenolate mofetil (MMF) is an anti-proliferative agent that is used in heart transplantation (HTx). The multicenter randomized trial of mycophenolate…”
Get full text

Effect of the Shingles Vaccine in Altering Clinical Shingles after Heart Transplantation by Kittleson, M., Patel, J., Chang, D., Nishihara, K., Shen, A., Velleca, A., Hamilton, M., Zakowski, P., Czer, L., Esmailian, F., Kobashigawa, J.

“…Herpes zoster, otherwise known as shingles, can be a devastating complication after heart transplantation due to persistent and severe herpetic neuralgia. Our…”
Get full text

5-Year Outcome of Patients Weaned off Corticosteroids after Heart Transplantation: Is There a Downside? by Patel, J., Kittleson, M., Chang, D.H., Nishihara, K., Shen, A., Sharoff, R., Velleca, A., Coleman, B., Hage, A., Czer, L., Ramzy, D., Kobashigawa, J.A.

“…A large number of heart transplant patients are weaned off corticosteroids within the first year after heart transplantation. These patients are selected as…”
Get full text

Pre-Transplant Collagen Vascular Disease as a Risk Factor for Increase in Cardiac Allograft Vasculopathy after Heart Transplantation by Patel, J., Kittleson, M., Chang, D., Nishihara, K., Shen, A., Harris, G., Velleca, A., Azarbal, B., Czer, L., Ramzy, D., Kobashigawa, J.

“…Collagen vascular disease, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and scleroderma (SSc), all have auto-antibodies in their…”
Get full text

Longer-Term Morbidity/Mortality of Severe Left Ventricular Primary Graft Dysfunction after Heart Transplantation by Kittleson, M., Patel, J., Chang, D., Nishihara, K., Shen, A., Patel, A., Velleca, A., Azarbal, B., Czer, L., Emerson, D., Trento, A., Kobashigawa, J.

“…Severe primary graft dysfunction (PGD) is seen in approximately 5% of all heart transplant recipients per the International Society for Heart and Lung…”
Get full text

Has the New Heart Transplant Donor Allocation Policy Affected Immediate Post-Transplant Care and Outcomes? A Single Center Perspective by Ramzy, D., Esmailian, F., Emerson, D., Megna, D., Levine, R., Mersola, S., Cole, R., Passano, E., Runyan, C., Velleca, A., Kobashigawa, J., Moriguchi, J.

“…The new UNOS donor heart allocation policy began in October 2018 and prioritized the sickest patients on the heart transplant waitlist. Patients on ECMO and on…”
Get full text

Donor Specific Antibodies after Heart Transplantation: Can They Be Treated? by Aiken, A., Patel, J., Kransdorf, E., Shen, A., Nishihara, K., Velleca, A., Cole, R., Hamilton, M., Czer, L., Megna, D., Zhang, X., Kobashigawa, J.

“…The development of post-transplant donor specific antibody (DSA), especially those that bind complement (C1q+), has been associated with development of cardiac…”
Get full text

Intravenous Methamphetamine Does Not Appear to Be a Contraindication for Heart Donation in Heart Transplantation by Velleca, A., Kao, T., Kearney, B., Patel, J., Kittleson, M., Levine, R., Dimbil, S., Mersola, S., Hamilton, M., Esmailian, F., Kobashigawa, J.

“…Intravenous methamphetamine (IV meth) use in potential heart donors has been of concern due to the possibility of methamphetamine cardiomyopathy and…”
Get full text

Heart Transplantation for Chagas Cardiomyopathy in the United States by Kransdorf, E. P., Czer, L. S. C., Luthringer, D. J., Patel, J. K., Montgomery, S. P., Velleca, A., Mirocha, J., Zakowski, P. C., Zabner, R., Gaultier, C. R., Qvarnstrom, Y., Benedict, T., Steurer, F., Bosserman, E., Paddock, C. D., Rafiei, M., Kobashigawa, J. A.

“…Since an initial case in 2006, we noted multiple patients undergoing heart transplantation (HTx) for Chagas cardiomyopathy (CC) at our transplant program. The…”
Get full text

802 Transplant Nursing around the Globe: What Are Nurses Reporting by Velleca, A, Coleman, B.L

Get full text

Is Tacrolimus/Proliferation Signal Inhibitor (PSI) Comparable to Cyclosporine/PSI After Heart Transplantation? by Chang, D, Kittleson, M, Patel, J, Aintablian, T, Velleca, A, Jamero, G, Kransdorf, E, Geft, D, Czer, L, Esmailian, F, Kobashigawa, J.A

Get full text

Predicted Heart Mass Is the Optimal Metric for Size Matching in Heart Transplantation by Kransdorf, E, Kittleson, M, Patel, J, Aintablian, T, Velleca, A, Stimpson, E, Geft, D, Chang, D.H, Czer, L, Trento, A, Kobashigawa, J.A

Get full text

Despite FDA Black Box Warning, Proliferation Signal Inhibitor (PSI) in the First Year with Induction Therapy Appears Safe in Heart Transplant Patients by Patel, J, Kittleson, M, Aintablian, T, Esmailian, G, Velleca, A, Hage, A, Kransdorf, E, Geft, D, Chang, D.H, Czer, L, Kobashigawa, J.A

Get full text

ACE Inhibitors or ARBs - Do They Improve Outcome After Heart Transplantation? by Johl, M, Patel, J, Kittleson, M, Czer, L, Aintablian, T, Velleca, A, Hamilton, M, Geft, D, Chang, D.H, Ramzy, D, Kobashigawa, J.A

Get full text

Donor Heart Turn Down, Is It Rational? by Patel, J, Kittleson, M, Czer, L, Chang, D, Aintablian, T, Norris, E.C, Velleca, A, Rush, J, Stimpson, E, Hage, A, Trento, A, Kobashigawa

Get full text

Treatment of Sleep Apnea with Heart Transplantation: Does It Help? by Patel, J, Kittleson, M, Czer, L, Aintablian, T, Sharoff, R, Kim, B, Velleca, A, Kearney, B, Chang, D, Azarbal, B, Hamilton, M, Trento, A, Kobashigawa, J.A

Get full text

Vasoplegia After Heart Transplantation: Unraveling the Enigma by Esmailian, F, Perry, P, Luu, M, Patel, J, Kittleson, M, Czer, L, Aintablian, T, Zarrini, P, Velleca, A, Rush, J, Arabia, F, Kobashigawa, J.A

Get full text

Proliferation Signal Inhibitors Prevent Donor-Specific Antibody Production in Sensitized Patients after Heart Transplantation by Kittleson, M, Patel, J, Czer, L, Aintablian, T, Rodriguez, G, Velleca, A, Kearney, B, Chang, D, Hamilton, M, Esmailian, F, Zhang, X, Reinsmoen, N, Kobashigawa, J.A

Get full text